Emzor Pharmaceutical Successfully Repays Debut Series 1 Commercial Paper

Emzor Pharmaceutical Industries Ltd, a leading Nigerian pharmaceutical company, has announced the successful repayment of its inaugural Series 1 Commercial Paper, valued at ₦5.13 billion. The repayment, made on August 18, 2025, marks a significant milestone in the company’s capital markets journey. Emzor’s timely repayment underscores its robust financial management and commitment to financial discipline, […]

Emzor Pharmaceutical Industries Ltd, a leading Nigerian pharmaceutical company, has announced the successful repayment of its inaugural Series 1 Commercial Paper, valued at ₦5.13 billion. The repayment, made on August 18, 2025, marks a significant milestone in the company’s capital markets journey.

Emzor’s timely repayment underscores its robust financial management and commitment to financial discipline, further reinforced by its investment-grade credit rating of A- with a stable outlook.

Emzor has scaled up local Active Pharmaceutical Ingredients (API) production with a $23 million investment in a state-of-the-art facility in Sagamu, Ogun State, set to bolster Nigeria’s drug self-sufficiency.

Emzor has implemented advanced ERP and track-and-trace software systems to ensure quality and consumer safety, eliminating substandard and counterfeit medications.

Emzor reaffirmed its pivotal role in enhancing medicine security across West Africa, with over 200 registered products and distribution to all Nigerian states and West Africa.

Emzor commends the Nigerian government’s policies bolstering local pharmaceutical production, including: Exemption of pharmaceutical raw materials from import duties and VAT for two years.

A new economic directive prioritizing procurement of locally manufactured goods.

With its landmark API facility nearing completion and expanding footprint, Emzor remains at the forefront of building resilient, accessible healthcare across Africa.